Pulmonx Corporation

NASDAQ:LUNG

Medical - Devices

Healthcare
$2.69 +3.60%

+$0.05 today

Market cap
$117.15M
Beta
0.28
P/E (TTM)
-1.0
EPS (TTM)
-$1.27
52W Low $1.13High $3.88

Volume 0.48M

Average 0.44M

LUNG EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Pulmonx CorporationNASDAQ: LUNG

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$12.31M, compared with -$14.56M a year earlier. Trailing-twelve-month EBITDA was -$48.22M.

Context

  • EBITDA amounted to 54.3% of revenue in FY2025, down 6.3 pp from a year earlier.
  • EBITDA grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of -$34.33M (+30.2%) for the fiscal year ending Dec 2026, a step up from the +3.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$12.31M-33.2% QoQ
Last fiscal yearDec 2025
-$49.17M+3.2% YoY
LTMMar 2026
-$48.22M+9.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.5%+23.4%+7.9 pp
1 year+3.2%+30.2%+27.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(49.17M) USD
Year-over-year change
+3.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How LUNG compares with its peers on the latest reported figures

  • LUNG's LTM Mar 2026 EBITDA of -$48.22M is the 5th highest of the 10 companies compared; the peer median is -$58.88M.
  • Its year-over-year change of +9.4% is the 3rd highest of 10, against a peer median of +0.7%.
  • EBITDA amounts to 54.5% of revenue for LUNG, versus a peer median of 41.4%.
LUNG Competitors Peer median
EBITDA for LUNG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VXRTVaxart, Inc.LTM Mar 2026$47.3M +203.4%—18.5%
ASRTAssertio Holdings, Inc.LTM Mar 2026-$5.79M -288.4%-67.3%5.7%
TELATELA Bio, Inc.LTM Jun 2026-$33.12M +4.6%—41.4%
HYPRHyperfine, Inc.LTM Mar 2026-$33.15M +15.7%—216.2%
LUNGPulmonx CorporationLTM Mar 2026-$48.22M +9.4%—54.5%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026-$58.88M -297.6%——
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026-$78.19M +0.2%——
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026-$82.08M +0.7%——
IMUXImmunic, Inc.LTM Mar 2026-$104.13M -8.2%——
TCRXTScan Therapeutics, Inc.LTM Mar 2026-$118.65M +4.8%—1298.7%
Peer median (excluding LUNG) -$58.88M+0.7%-67.3%41.4%

Competitors are the stored peer set for LUNG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.42M53.66M68.68M83.79M90.5M
Cost of Revenue12.79M13.8M17.92M21.79M23.36M
Gross Profit35.63M39.87M50.75M62M67.14M
Gross Margin73.6%74.3%73.9%74.0%74.2%
Research & Development13.06M15.4M18.08M17.57M19.49M
Selling, General & Admin69.87M83.11M94.61M102.14M101.31M
Operating Expenses82.93M98.5M112.69M119.71M120.8M
Depreciation & Amortization867K1.51M1.95M1.59M1.05M
EBITDA(46.62M)(55.99M)(55.09M)(50.79M)(49.17M)
EBITDA Margin-96.3%-104.3%-80.2%-60.6%-54.3%
Operating Income(47.3M)(58.64M)(61.94M)(57.7M)(53.66M)
Operating Margin-97.7%-109.3%-90.2%-68.9%-59.3%
Interest Income400K1.53M5.57M5.06M2.65M
Interest Expense829K1.07M3.23M3.51M3.16M
Other Income / Expenses(1.01M)67K1.66M1.81M286K
Income Before Tax(48.32M)(58.57M)(60.27M)(55.89M)(53.38M)
Pre-Tax Margin-99.8%-109.1%-87.8%-66.7%-59.0%
Income Tax Expense343K353K571K500K626K
Net Income(48.66M)(58.92M)(60.84M)(56.39M)(54M)
Net Margin-100.5%-109.8%-88.6%-67.3%-59.7%
EPS (Basic)(1.35)(1.59)(1.60)(1.44)(1.33)
EPS (Diluted)(1.35)(1.59)(1.60)(1.44)(1.33)
Weighted Avg Shares36.13M37.1M37.97M39.11M40.69M
Weighted Avg Shares (Diluted)36.13M37.1M37.97M39.11M40.69M

Pulmonx Corporation

NASDAQ:LUNG

Intrinsic Alpha fair value

Locked

Current Price

$2.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.